Search

Your search keyword '"Arriens, A."' showing total 407 results

Search Constraints

Start Over You searched for: Author "Arriens, A." Remove constraint Author: "Arriens, A."
407 results on '"Arriens, A."'

Search Results

1. Phenological mismatch is less important than total nectar availability for checkerspot butterflies.

2. Radiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine

3. Radiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine

7. O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

8. Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype

9. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.

10. Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE

12. Cell-bound complement activation products associate with lupus severity in SLE.

13. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

14. Ancestry-based differences in the immune phenotype are associated with lupus activity

16. Factors associated with immune responses to SARS-CoV-2 vaccination in autoimmune disease individuals

18. POS0527 DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): EFFICACY BY BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN THE PHASE 2 PAISLEY TRIAL

20. POS0191 A LUPUS FLARE RISK INDEX INFORMED BY SELECT ADAPTIVE AND TNF SUPERFAMILY IMMUNE MEDIATORS: VALIDATION IN A CONFIRMATORY COHORT

21. OP0255 SELECT SOLUBLE MEDIATORS INFORM A REFINED LUPUS DISEASE ACTIVITY IMMUNE INDEX THAT CHARACTERIZES CLINICAL DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS

28. Untersuchung

30. Adressen

32. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus

33. What we are missing for SDG6: Water leaders at all levels in our workplaces.

34. A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus

38. O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

41. Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies

42. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus

43. A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus

44. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers

45. Cell-bound complement activation products associate with lupus severity in SLE

46. Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study

47. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial

48. Ancestry-based differences in the immune phenotype are associated with lupus activity

49. Safety and efficacy of long‐term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial

Catalog

Books, media, physical & digital resources